| ALCON RESEARCH, LTD. Patent applications |
| Patent application number | Title | Published |
|---|
| 20120116216 | Low Viscosity, Highly Flocculated Triamcinolone Acetonide Suspensions for Intravitreal Injection - Triamcinolone acetonide suspension compositions are disclosed. The suspension compositions have a relatively low viscosity and are easy to extrude through a 27- or 30-gauge needle but are highly flocculated and easily redispersed. The compositions are particularly suitable for intravitreal injection. | 05-10-2012 |
| 20120115870 | CONTROL OF INTRAOCULAR PRESSURE USING ALK5 MODULATION AGENTS - An ophthalmic pharmaceutical composition useful in the treatment of glaucoma and control of intraocular pressure comprising an effective amount of a selective modulator of ALK5 receptor activity is disclosed. Also disclosed is a method of treating glaucoma and controlling intraocular pressure comprising applying a therapeutically effective amount of a pharmaceutical composition comprising a selective modulator of ALK5 receptor activity to an affected eye of a patient. | 05-10-2012 |
| 20120115829 | Low Viscosity, Highly Flocculated Triamcinolone Acetonide Suspensions for Intravitreal Injection - Triamcinolone acetonide suspension compositions are disclosed. The suspension compositions have a relatively low viscosity and are easy to extrude through a 27- or 30-gauge needle but are highly flocculated and easily redispersed. The compositions are particularly suitable for intravitreal injection. | 05-10-2012 |
| 20120108632 | PRENYLTRANSFERASE INHIBITORS FOR OCULAR HYPERTENSION CONTROL AND THE TREATMENT OF GLAUCOMA - The invention concerns in one embodiment a method of treating glaucoma or elevated intraocular pressure comprising administering a pharmaceutically effective amount of a composition comprising at least one prenyltransferase inhibitor. In another embodiment, the invention concerns a composition for the treatment of elevated intraocular pressure and glaucoma comprising a pharmaceutically effective amount of a prenyltransferase inhibitor. | 05-03-2012 |
| 20120108557 | FLUOROQUINOLONE DERIVATIVES FOR OPHTHALMIC APPLICATIONS - The present invention relates to fluoroquinolone derivatives having enhanced ocular penetration characteristics and/or antimicrobial activity, and to compositions comprising such derivatives. The derivatives and compositions are particularly well suited for treating ophthalmic bacterial infections. The present invention more particularly relates to the discovery that a 2-methyl substitution on a diazabicyclo group attached to a fluoroquinolone ring system produces improved permeability characteristics, and that a 5-amino substitution on a fluoroquinolone ring system results in improved anti-microbial activity. | 05-03-2012 |
| 20120077864 | RNAI-MEDIATED INHIBITION OF GREMLIN FOR TREATMENT OF IOP-RELATED CONDITIONS - RNA interference is provided for inhibition of gremlin in intraocular pressure-related conditions, including ocular hypertension and glaucoma such as normal tension glaucoma and open angle glaucoma. | 03-29-2012 |
| 20120070402 | POLYMERIC ARTIFICIAL TEAR SYSTEM - The present invention relates to artificial tear formulations and ophthalmic formulations suitable for drug delivery. The formulations comprise galactomannans such as guar or hydroxypropyl guar and a borate source such as boric acid. The formulations further comprise a cis-diol such as sorbitol that interferes with the cross-linking of galactomannan and borate. Optionally, the formulations are substantially free of divalent cations. | 03-22-2012 |
| 20120065187 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE - The present invention relates to compounds and methods which may be useful as inhibitors of H | 03-15-2012 |
| 20120046285 | BRADYKININ RECEPTOR AGONISTS AND USES THEREOF TO TREAT OCULAR HYPERTENSION AND GLAUCOMA - The invention provides compositions and methods for treating and/or preventing ocular disorders associated with increased intraocular pressure. In particular, the compounds are bradykinin agonists. | 02-23-2012 |
| 20120038222 | Self-Matching Pulse Generator with Adjustable Pulse Width and Pulse Frequency - Pulse-generator circuits that permit independent control of pulse widths and the delays between successive pulses. In several embodiments, a pulse-generator subcircuit includes a transmission-line segment comprising first and second conductors, configured such that the first conductor is coupled to a first DC potential. The pulse-generator subcircuit further includes a terminating resistor coupled to a first end of the second conductor of the first transmission-line segment; this terminating resistor is matched to the characteristic impedance of the transmission-line segment. The pulse-generator subcircuit further includes first and second switches, controlled by first and second timing signals, respectively, and configured to selectively and independently connect respective first and second ends of the first conductor to a second DC potential. This second potential may be ground, in some embodiments, while the DC potential supplied to the pulse-generator subcircuit by the power-supply subcircuit may range from a very small voltage to voltages exceeding a kilovolt. | 02-16-2012 |
| 20120029051 | siRNA Targeting VEGFA and Methods for Treatment In Vivo - Vascular endothelial growth factor A (VEGFA) is a chemical signal produced by cells that stimulates the growth of new blood vessels, and overexpression of VEGFA can lead to undesirable physiological conditions. Through the identification of new siRNA and modifications that improve the silencing ability of these siRNA in vivo, therapeutic compositions and methods have been invented to address the problems associated with this overexpression. | 02-02-2012 |
| 20120004528 | Implantable Remote Monitoring Sensor - An exemplary implantable sensor includes a housing that generally conforms to a curvature of an anterior chamber of a patient's eye. A sensing device disposed in the housing is configured to detect physiological parameters and transmit a signal representing the physiological parameters. The exemplary sensor may be used to detect physiological parameters such as intraocular pressure, flow velocity of aqueous humor, blood sugar, and blood biochemicals. | 01-05-2012 |
| 20120004245 | COMPOUNDS FOR THE TREATMENT OF POSTERIOR SEGMENT DISORDERS AND DISEASES - The use of certain urea compounds, for the treatment of retinal disorders associated with pathologic ocular angiogenesis and/or neovascularization is disclosed. | 01-05-2012 |
| 20110319810 | Curved Infusion Sleeve - An infusion sleeve, infusion sleeve assembly, and method of making the same are disclosed. An exemplary infusion sleeve assembly may include a tubular body and a tip inserted into the body. The tubular body may include an insertion end and an attachment end. The insertion end may define a tip aperture and a first fluid aperture adjacent the tip aperture, while the attachment end may be configured to be secured to a surgical tool for fluid exchange therewith. The tubular body includes a curved portion between the insertion end and attachment end such that a first axis of the insertion end is angled relative to a second axis of the attachment end. Further, the tubular body may define a substantially smooth surface throughout the curved portion. | 12-29-2011 |
| 20110313343 | Phacoemulsification Fluidics System Having a Single Pump Head - A phacoemulsification fluidics system for irrigating and aspirating a surgical site includes a sterile solution reservoir, an irrigation path configured to extend from the sterile solution reservoir to the surgical site, and an aspiration path configured to extend from the surgical site. The system also includes a single flow control pump head associated with both the irrigation path and the aspiration path. The flow control pump head is arranged within the system to simultaneously pressurize the irrigation path in a manner that drives the irrigation fluid to the surgical site and pressurize the aspiration path in a manner that vacuums waste fluid from the surgical site. | 12-22-2011 |
| 20110301425 | Inductive Task Light For Surgical Console - A task light system for a surgical console includes a task light that can be held to a coupling location on a surgical console. The task light has an inductive coupling, a light source, and a goose neck connecting the light source to the inductive coupling. The coupling location is located on a face of the surgical console. The coupling location is configured to magnetically attract and hold the inductive coupling. The face of the surgical console where the coupling location is located is a continuous surface. | 12-08-2011 |
| 20110300019 | USE OF PBO-PEO-PBO BLOCK COPOLYMERS IN OPHTHALMIC COMPOSITIONS - The use of poly(oxybutylene)-poly(oxyethylene)-poly(oxybutylene) block copolymers in pharmaceutical compositions useful, for modifying the surfaces of contact lenses and other medical devices is disclosed. The present invention is based in-part on a discovery that this class of compounds is particularly efficient in wetting hydrophobic surfaces, such as the surfaces of silicone hydrogel contact lenses and other types of ophthalmic lenses, but do not induce foaming when used in conjunction with a peroxide-based contact lens disinfection regimen. Such compounds may also be useful for cleaning purposes. The use of the compounds as surfactants in peroxide-based compositions for disinfecting contact lenses therefore represents a preferred embodiment of the present invention. | 12-08-2011 |
| 20110295191 | Infusion Pressure Monitoring System - An infusion pressure monitoring system for a phacoemulsification or vitrectomy machine to be operated by a health care provider includes an irrigation path configured to carry an irrigation solution to a surgical site and a fluid sensor configured to detect a fluid parameter in the irrigation path. An input device receives a variable fluid flow command from the health care provider commanding an irrigation fluid flow through the irrigation path at a flow rate corresponding to the command. A controller communicates with both the fluid sensor and the input device. The controller determines an expected fluid pressure value and a dynamically variable threshold pressure value based upon the variable fluid flow command. | 12-01-2011 |
| 20110288157 | RNAi-Mediated Inhibition of Spleen Tyrosine Kinase-Related Inflammatory Conditions - RNA interference is provided for inhibition of spleen tyrosine kinase (Syk) mRNA expression, in particular, for treating patients having a Syk-related inflammatory condition or at risk of developing a Syk-related inflammatory condition such as allergic conjunctivitis, ocular inflammation, dermatitis, rhinitis, asthma, allergy, or mast-cell disease. | 11-24-2011 |
| 20110288101 | SURGICAL COMPOSITIONS CONTAINING SIGMA-RECEPTOR AGONISTS - One aspect of the present invention relates to aqueous surgical compositions comprising a sigma-1 receptor agonist. Another aspect of the present invention relates to methods of irrigating ocular tissues during an ophthalmic surgical procedure such as cataract surgery. Such methods comprise bathing the ocular tissues with a composition comprising a sigma-1 receptor agonist. | 11-24-2011 |
| 20110275593 | STABILIZED OPHTHALMIC GALACTOMANNAN FORMULATIONS - The present invention relates to viscosity stabilized ophthalmic formulations and ophthalmic formulations suitable for drug delivery. The formulations comprise galactomannans such as guar or hydroxypropyl guar and a borate source such as boric acid. The formulations further comprise a diol alcohol such as sorbitol and, optionally, a pharmaceutically acceptable divalent cation salt such as magnesium chloride. | 11-10-2011 |
| 20110274322 | DEVICES AND METHODS FOR ASSESSING CHANGES IN CORNEAL HEALTH - A computer-implemented method for use in assessing a cornea which includes selecting a principal image from among a series of layered images of the cornea. The computer-implemented method further includes detecting a plurality of corneal structures in the principal image and providing a quantitative analysis of the plurality of corneal structures. | 11-10-2011 |
| 20110269822 | RNAi-Mediated Inhibition of Histamine Receptor H1-Related Conditions - RNA interference is provided for inhibition of histamine receptor H1 mRNA expression, in particular, for treating patients having an HRH1-related condition or at risk of developing an HRH1-related condition such as allergic conjunctivitis, ocular inflammation, dermatitis, rhinitis, asthma, or allergy. | 11-03-2011 |
| 20110257658 | Modular Intraocular Lens Injector Device - An intraocular lens (IOL) injection device is modularized to enable cleaning of internal components after surgery. The device includes first and second housing modules. These modules collectively define a passageway along which an injector rod moves between a retracted position and an extended position. The first module is further configured to accommodate a lens cartridge module. The cartridge module has disposed therein an IOL, in alignment with the passageway. Thus as the rod moves from the retracted position to the extended position, a front portion of the rod that is substantially surrounded by the first module in the retracted position moves into the cartridge module and displaces the IOL. This causes the front portion of the rod to accumulate on it viscoelastic substances. The first module, though, is configured to detach from the second module, to thereby expose the front portion of the rod in the retracted position for cleaning. | 10-20-2011 |
| 20110257248 | RNAi-RELATED INHIBITION OF TNFa SIGNALING PATHWAY FOR TREATMENT OF OCULAR ANGIOGENESIS - RNA interference is provided for inhibition of tumor necrosis factor α (TNFα) by silencing TNFα cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNFα converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNFα targets, in particular, is useful for treating patients having a TNFα-related condition or at risk of developing a TNFα-related condition, such as ocular angiogenesis, retinal ischemia, and diabetic retinopathy. | 10-20-2011 |
| 20110257246 | RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESIS - RNA interference is provided for inhibition of HIF1A mRNA expression for treating patients with ocular angiogenesis, particularly for treating retinal edema, diabetic retinopathy, sequela associated with retinal ischemia, posterior segment neovascularization (PSNV), and neovascular glaucoma, and for treating patients at risk of developing such conditions. | 10-20-2011 |
| 20110256156 | TRANSFERRIN/TRANSFERRIN RECEPTOR-MEDIATED siRNA DELIVERY - The invention provides interfering RNA molecule-ligand conjugates useful as a delivery system for delivering interfering RNA molecules to a cell in vitro or in vivo. The conjugates comprise a ligand that can bind to a transferrin receptor (TfR). Therapeutic uses for the conjugates are also provided. | 10-20-2011 |
| 20110248671 | Power System Implantable in Eye - An implantable ophthalmic power system includes a power source and an enclosure. The enclosure surrounds the power source. The enclosure is configured to be implanted under the conjunctiva of the eye. | 10-13-2011 |
| 20110245319 | RNAi-Mediated Inhibition of RHO Kinase for Treatment of Ocular Disorders - RNA interference is provided for inhibition of Rho kinase mRNA expression for treating patients with ocular disorders, particularly for treating intraocular pressure, ocular hypertension and glaucoma. Rho kinase mRNA targets include mRNA for ROCK1 and ROCK2. | 10-06-2011 |
| 20110230877 | Pulsed Electric Field Probe for Glaucoma Surgery - A small gauge pulsed electric field/aspirator probe. The probe has a generally cylindrical cannula with a generally smooth distal end. A port is located near a distal end of the cannula on a side of the cannula. A pair of electrodes is located at the port. An electric pulse generator is coupled to the pair of electrodes. A distance between the distal end of the cannula and the port is approximately equal to the distance between a back wall of Schlemm's canal and a trabecular meshwork in a human eye. The electric pulse generator applies a pulsed electric field to the pair of electrodes sufficient to dissociate protein bonds that hold the trabecular meshwork together. | 09-22-2011 |
| 20110230410 | LOW DENSITY LIPOPROTEIN RECEPTOR-MEDIATED siRNA DELIVERY - The invention provides interfering RNA molecule-ligand conjugates useful as a delivery system for delivering interfering RNA molecules to a cell in vitro or in vivo. The conjugates comprise a ligand that can bind to a low density lipoprotein receptor (LDLR) or LDLR family member. Therapeutic uses for the conjugates are also provided. | 09-22-2011 |
| 20110207809 | METHOD OF ACCELERATING CORNEAL WOUND HEALING - The topical ophthalmic use of 5,6,7-trihydroxyheptanoic acid and analogs for the acceleration of corneal wound healing in humans, is disclosed. | 08-25-2011 |
| 20110202049 | Small Gauge Ablation Probe For Glaucoma Surgery - An ablation probe for use in glaucoma surgery has a shaft, a heating element, and a pair of electrical connectors located on a distal end of the shaft. The pair of electrical connectors holds the heating element to the shaft. The heating element is sized and shaped to ablate a trabecular meshwork in a human eye. The ablation probe is advanced through a corneal incision until the heating element contacts the trabecular meshwork. An electrical current is passed through the heating element to ablate the trabecular meshwork. | 08-18-2011 |
| 20110195962 | USE OF MULTI-PHARMACOPHORE COMPOUNDS TO TREAT NASAL DISORDERS - Compositions and methods for treating nasal disorders associated with nasal inflammation using a multipharmacophoric agent (MPA) that can prevent the production and/or release of at least one or more pro-inflammatory cytokines (for instance IL-1 and TNFα) and inhibit p | 08-11-2011 |
| 20110195132 | Self-Preserved Aqueous Pharmaceutical Compositions - The present invention is directed to the provision of multi-dose, self-preserved ophthalmic compositions. The compositions possess sufficient antimicrobial activity to satisfy USP preservative efficacy requirements, as well as similar preservative standards (e.g., EP and JP), without requiring the presence of conventional anti-microbial preservative agents, such as benzalkonium chloride. The compositions are effectively preserved by a balanced ionic buffer system containing zinc ions at a concentration of 0.04 to 0.9 mM, preferably 0.04 to 0.4 mM. One aspect of the balanced buffer system is limitation of the amount of buffering anions present to a concentration of 15 mM or less, preferably 5 mM or less. In a preferred embodiment, the compositions also contain borate or, most preferably, one or more borate/polyol complexes. The use of propylene glycol as the polyol in such complexes is strongly preferred. Limiting the amount of divalent metals other than zinc and the amount of ionized salts present has also been determined to be important to maximize the antimicrobial activity of the balanced buffer systems. | 08-11-2011 |
| 20110190376 | RNAi-RELATED INHIBITION OF TNFa SIGNALING PATHWAY FOR TREATMENT OF MACULAR EDEMA - RNA interference is provided for inhibition of tumor necrosis factor α (TNFα) by silencing TNFα cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNFα converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNFα targets, in particular, is useful for treating patients having or at risk of developing macular edema. | 08-04-2011 |
| 20110164218 | METHOD AND APPARATUS FOR OCULAR SURFACE IMAGING - The invention provides apparatuses and methods for detecting ocular surface defects. The methods and/or an apparatus of the invention can be used to detect ocular surface diseases, such as dry eye, uveitis, conjunctivitis, keratitis, keratoconjunctivitis, vernal keratoconjunctivitis (VKC), atopic keratoconjunctivitis (AKC), autoimmune disorders of the ocular surface, meibomianitis, conjunctival hyperemia, eyelid hyperemia, ocular rosacea, ocular inflammation, or eye lid swelling. | 07-07-2011 |
| 20110160308 | Use of Monoamine Oxidase Inhibitors to Treat Outer Retina Disorders - Compositions and methods for treating disorders of the outer retina with compounds that inhibit monoamine oxidase are disclosed. | 06-30-2011 |
| 20110160172 | FLUOROQUINOLONE DERIVATIVES FOR OPHTHALMIC APPLICATIONS - The present invention relates to fluoroquinolone derivatives having enhanced ocular penetration characteristics and/or antimicrobial activity, and to compositions comprising such derivatives. The derivatives and compositions are particularly well suited for treating ophthalmic bacterial infections. The present invention more particularly relates to the discovery that a 2-methyl substitution on a diazabicyclo group attached to a fluoroquinolone ring system produces improved permeability characteristics, and that a 5-amino substitution on a fluoroquinolone ring system results in improved anti-microbial activity. | 06-30-2011 |
| 20110151017 | OPHTHALMIC SOLUTIONS WITH IMPROVED DISINFECTION PROFILES - The present invention relates to ophthalmic solutions with antimicrobial activity. The solutions have an antimicrobial compound such as hydrogen peroxide and a boron compound. In one embodiment, the solutions contain a boron compound such as sodium borate that provides antimicrobial activity in addition to that of hydrogen peroxide, particularly during periods following disinfection and neutralization of such solutions. This additional activity reduces the likelihood of microbial growth in contact lens disinfection applications that neutralize hydrogen peroxide. | 06-23-2011 |
| 20110144641 | High-Intensity Pulsed Electric Field Vitrectomy Apparatus - A high-intensity pulsed electric field (HIPEF) vitrectomy apparatus is disclosed. An exemplary apparatus includes a HIPEF probe comprising at least one electrode disposed at a distal end of the HIPEF probe, such that the distal end is configured for insertion into an eye. Various embodiments include a probe shaft assembled from a modular end segment and one or more additional modular shaft segments, each of the modular end segment and one or more modular shaft segments in turn comprising at least two longitudinal channels adapted to accommodate an electrode unit. In some of these probe shafts, each of the modular end segment and one or more modular shaft segments has a central longitudinal channel, and the probe shaft further comprises an aspiration tube disposed within the central longitudinal channel. | 06-16-2011 |
| 20110144638 | Localized Shockwave-Induced Tissue Disruption - A high-intensity pulsed-electrical-field (HIPEF) apparatus removes ocular tissue from a localized portion of an eye by delivering one or more focused shockwaves to that tissue. In one embodiment, for example, the apparatus generates one or more electrical pulses, delivers the one or more focused shockwaves to ocular tissue by applying the generated electrical pulses to a HIPEF probe, and then removes the ocular tissue disrupted by the one or more focused shockwaves via aspiration. To mitigate risk of damage to adjacent ocular tissue, the apparatus delivers the one or more focused shockwaves with energy substantially limited to the tissue being removed. The HIPEF apparatus is, therefore, especially advantageous in the context of cataract surgery where cataract tissue need be broken apart and removed without damaging adjacent tissue associated with the lens capsule required to implant an intraocular lens. | 06-16-2011 |
| 20110144567 | Phacoemulsification Hand Piece With Integrated Aspiration Pump and Cartridge - An ophthalmic surgical hand piece comprises a driver coupled to a horn. The horn is coupled to a needle. An aspiration pump is integral with the hand piece and is located close to the needle. The aspiration pump comprises a motor coupled to a shaft. A removable cartridge comprises a length of flexible tubing held by a tubing holder. The length of flexible tubing is located between the shaft and the tubing holder. The removable cartridge comprises a section of an aspiration line. | 06-16-2011 |
| 20110144562 | Localized Pharmacological Treatment of Ocular Tissue Using High-Intensity Pulsed Electrical Fields - A high-intensity pulsed-electrical-field (HIPEF) apparatus treats ocular tissue within a localized portion of an eye with a pharmacological solution. To mitigate risk of damage to adjacent, healthy ocular tissue, the apparatus delivers the solution to only a portion of the eye and then alters the effectiveness of at least some of the solution delivered by applying a HIPEF. In some embodiments, for example, the apparatus delivers an inactive pharmacological solution and then activates at least some of the solution by applying a HIPEF to that solution. As the apparatus applies the HIPEF with high precision, the HIPEF only activates solution within select portions of the eye. In other embodiments, the apparatus delivers a pharmacological carrier encapsulating an active pharmacological solution and then penetrates the carrier by applying a HIPEF. Delivered with a high concentration, but low dose, the solution diffuses only to tissue within a localized portion of the eye. | 06-16-2011 |
| 20110142767 | RNAi-MEDIATED INHIBITION OF TUMOR NECROSIS FACTOR ALPHA-RELATED CONDITIONS - RNA interference is provided for inhibition of tumor necrosis factor α (TNFα) by silencing TNFα cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNFα converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNFα targets, in particular, is useful for treating patients having a TNFα-related condition or at risk of developing a TNFα-related condition such as the ocular conditions dry eye, allergic conjunctivitis, or ocular inflammation, or such as dermatitis, rhinitis, or asthma, for example. | 06-16-2011 |
| 20110137232 | Thermal Management Algorithm For Phacoemulsification System - A control system for managing power supplied to a phacoemulsification hand piece includes a power source that provides power to the hand piece and a controller that controls the power source. The controller calculates a thermal value based on irrigation fluid flow and a power level and decreases the power level in proportion to the calculated thermal value when the calculated thermal value exceeds a threshold thermal value. Irrigation fluid flow can be calculated from irrigation fluid pressure. | 06-09-2011 |
| 20110137231 | Phacoemulsification Hand Piece With Integrated Aspiration Pump - An ophthalmic surgical hand piece comprises a driver coupled to a horn. The horn is coupled to a needle. An aspiration pump is integral with the hand piece and is located close to the needle. A rigid length of aspiration line is located between the aspiration pump and the needle. An optional pressure sensor is located between the aspiration pump and the needle as well. | 06-09-2011 |
| 20110135743 | CARBOXYVINYL POLYMER-CONTAINING NANOPARTICLE SUSPENSIONS - The present invention generally relates to suspension compositions having a carboxyvinyl polymer such as a carbomer, a galactomannan such as guar, and a borate compound. A sparingly soluble particulate compound such as nepafenac is also included in the compositions. The sparingly soluble particulate compound has a small particle size to enhance bioavailability of the compound. | 06-09-2011 |
| 20110135626 | Localized Chemical Lysis of Ocular Tissue - A high-intensity pulsed-electrical-field (HIPEF) apparatus chemically induces lysis of ocular tissue within a localized portion of an eye. Instead of broadly applying a lysis affecting solution (e.g., plasmin) to the eye, the apparatus delivers solution to only a portion of the eye. The apparatus then alters the effectiveness of at least some of the solution delivered by applying a HIPEF to that solution. In some embodiments, for example, the apparatus delivers a solution that does not substantially affect lysis of ocular tissue and then enhances the solution's effectiveness by applying a HIPEF. As the apparatus applies the HIPEF with high precision, the HIPEF only enhances the effectiveness of the solution within select and localized portions of the eye. The apparatus is especially advantageous for vitreoretinal surgery, whereby the apparatus may selectively induce lysis of vitreous tissue within a localized portion of the vitreous cavity, without significantly affecting adjacent retinal tissue. | 06-09-2011 |
| 20110135579 | RNAi-RELATED INHIBITION OF TNFa SIGNALING PATHWAY FOR TREATMENT OF GLAUCOMA - RNA interference is provided for inhibition of tumor necrosis factor α (TNFα) by silencing TNFα cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNFα converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNFα targets, in particular, is useful for treating patients having a TNFα-related condition or at risk of developing a TNFα-related condition such as the ocular conditions associated with elevated intraocular pressure (IOP), including glaucoma and ocular hypertension. | 06-09-2011 |
| 20110124734 | N-HALOGENATED AMINO ACID FORMULATIONS AND METHODS FOR CLEANING AND DISINFECTION - The present invention relates to methods for disinfecting or cleaning a contact lens comprising contacting a contact lens with a formulation comprising a N-halogenated amino acid and a phase transfer agent for a time sufficient to disinfect or clean the lens. This specification further discloses a formulation for disinfecting a contact lens comprising an N-halogenated amino acid and a phase transfer agent. | 05-26-2011 |
| 20110118734 | CAPSULARHEXIS DEVICE USING PULSED ELECTRIC FIELDS - A capsulorhexis apparatus is disclosed. An exemplary apparatus includes a cutting electrode device that in turn comprises a handle, a flexible ring having a single ring-shaped wire electrode embedded therein, and a shaft connecting the flexible ring to the handle, wherein the flexible ring is configured for insertion into an eye through an incision. The apparatus further includes a grounding electrode configured for placement in or on the eye, independently of the cutting electrode device, and a pulse generator electrically connected to the ring-shaped wire electrode and the grounding electrode and configured to supply pulsed power to the eye via the ring-shaped wire electrode and the grounding electrode | 05-19-2011 |
| 20110118729 | HIGH-INTENSITY PULSED ELECTRIC FIELD VITRECTOMY APPARATUS WITH LOAD DETECTION - A high-intensity pulsed electric field (HIPEF) vitrectomy apparatus is disclosed. An exemplary apparatus includes a HIPEF probe comprising at least one electrode disposed at a distal end of the HIPEF probe, such that the distal end is configured for insertion into an eye. A load detection circuit is coupled to the HIPEF probe and is configured to compare a measured physical parameter to a corresponding threshold value. A control circuit is electrically coupled to the load detection circuit and configured to selectively disable application of pulsed energy to the at least one electrode of the HIPEF probe, based on the comparison. The measured physical parameter may include, for example, resistivity, permittivity, reflected light, pressure, or heat dissipation capability. | 05-19-2011 |
| 20110118728 | CONTROL OF HIGH-INTENSITY PULSED ELECTRICAL FIELDS IN SURGICAL APPLICATIONS - An eye surgery apparatus includes a HIPEF probe comprising at least two electrodes and is configured for delivery of a high-intensity pulsed electrical field to a surgical site within an eye via the electrodes. Embodiments also include a transducer configured to monitor one or more surgical parameters within the eye during application of the high-intensity pulsed electrical field to the surgical site, a pulse generation circuit configured to generate a series of electrical pulses for application to the electrodes to create the high-intensity pulsed electrical field, and a control circuit, operatively connected to the at least one transducer and the pulse generation circuit and configured to automatically adjust one or more characteristics of the series of electrical pulses, based on the one or more monitored surgical parameters. With these apparatus, the amount of energy delivered can be limited to levels necessary for effective operation without over-exposing the vitreous. | 05-19-2011 |
| 20110112038 | NOVEL NPR-B AGONISTS - Disclosed are novel compounds having NPR-B agonistic activity. Preferred compounds are linear peptides containing 8-13 conventional or non-conventional L- or D-amino acid residues connected to one another via peptide bonds. | 05-12-2011 |
| 20110111055 | NUTRITIONAL SUPPLEMENTS FOR RELIEF OF DRY EYE - The present invention provides improved dietary supplements and methods for alleviating the symptoms of dry eye. The dietary supplements of the invention contain omega-3 fatty acids and flavonoids. | 05-12-2011 |
| 20110105574 | PAI-1 EXPRESSION AND ACTIVITY INHIBITORS FOR THE TREATMENT OF OCULAR DISORDERS - The invention concerns in one embodiment a method for treating glaucoma or elevated IOP in a patient comprising administering to the patient an effective amount of a composition comprising an agent that inhibits PAI-1 expression or PAI-1 activity. Another embodiment of the present invention is a method of treating a PAI-1-associated ocular disorder in a subject in need, comprising administering to the patient an effective amount of a composition comprising an agent that inhibits PAI-1 activity or expression. | 05-05-2011 |
| 20110104154 | SINGLE NUCLEOTIDE POLYMORPHISMS AND GENES ASSOCIATED WITH AGE-RELATED MACULAR DEGENERATION - The invention provides genes and polymorphisms associated with AMD, and methods for diagnosing an increased risk of AMD in a patient who has at least one of the AMD-associated polymorphisms as provided. | 05-05-2011 |
| 20110092523 | AGENTS WHICH REGULATE, INHIBIT, OR MODULATE THE ACTIVITY AND/OR EXPRESSION OF CONNECTIVE TISSUE GROWTH FACTOR (CTGF) AS A UNIQUE MEANS TO BOTH LOWER INTRAOCULAR PRESSURE AND TREAT GLAUCOMATOUS RETINOPATHIES/OPTIC NEUROPATHIES - The present invention provides a method for lowering intraocular pressure and providing neuroprotection to a patient in need thereof by administering a therapeutically effective amount of at least one non-nucleotide or non-protein agent that inhibits expression and/or signaling of connective tissue growth factor (CTGF). | 04-21-2011 |
| 20110082145 | OLOPATADINE COMPOSITIONS AND USES THEREOF - The invention provides solution compositions comprising olopatadine and a PDE4 inhibitor compound of Formula I: | 04-07-2011 |
| 20110082125 | Topical Ophthalmic or Otic Solution Formulations Containing Moxifloxacin Hydrocholoride and Dexamethasone Phosphate - Topical ophthalmic and otic solution compositions of moxifloxacin and dexamethasone phosphate are disclosed. | 04-07-2011 |
| 20110082092 | INTERFERING RNA DELIVERY SYSTEM AND USES THEREOF - The invention provides a delivery system comprising a cell penetrating peptide, a polyarginine peptide, and an interfering RNA molecule. The system can be used for delivering interfering RNA molecules into a cell in vivo or in vitro. Therapeutic uses for the delivery system are also provided. | 04-07-2011 |
| 20110077381 | NOVEL NPR-B AGONISTS - Disclosed are novel compounds having NPR-B agonistic activity. Preferred compounds are linear peptides containing 8-13 conventional or non-conventional L- or D-amino acid residues connected to one another via peptide bonds. | 03-31-2011 |
| 20110071459 | Power Saving Glaucoma Drainage Device - A glaucoma drainage device has an active valve configured to be located between an anterior chamber of an eye and a drainage location, a power source coupled to the active valve, and a controller coupled to the power source. A first pressure sensor is located in fluid communication with the anterior chamber, a second pressure sensor is located in the drainage location, and a third pressure sensor located remotely from the first and second pressure sensors. The controller reads the first, second, and third pressure sensors once during a period of time and adjusts the active valve to control intraocular pressure. | 03-24-2011 |
| 20110071458 | Glaucoma Drainage Device with Pump - A glaucoma drainage device may comprise a main drainage tube with a first end configured to be located in an anterior chamber of an eye and a second end configured to be located in a drainage location. A bypass drainage tube is fluidly coupled to and in parallel with the main drainage tube. A pump is in communication with the bypass drainage tube. The pump comprises a first driver and a first flexible membrane enclosing a first chamber. A first check valve is located upstream of the pump, and a second check valve is located downstream of the pump. An active valve is located upstream of the first check valve. The active valve comprises a second driver and a second flexible membrane enclosing a second chamber. A third check valve is located between the active valve and the second end of the main drainage tube. A volume of the first chamber is changed to pump fluid from the anterior chamber to the drainage location. | 03-24-2011 |
| 20110071454 | Power Generator For Glaucoma Drainage Device - A glaucoma drainage device has a tube shunting the anterior chamber to a drainage location. A power generator has a rotor coupled to a micro-generator. The power generator is configured to generate energy from aqueous flowing through the tube. The force required to drive the rotor can be controlled to control the flow of aqueous through the tube. Alternatively, energy generated by the power generator is stored in a power source that powers an active valve, a pressure sensor, or telemetry. | 03-24-2011 |
| 20110071116 | ANTIMICROBIAL N-HALOGENATED AMINO ACID SALTS - The present invention relates to a formulation comprising a N-halogenated amino acid and a phase transfer agent. The present invention also describes a method for disinfecting and/or cleaning a contact lens comprising contacting a contact lens with a formulation comprising a N-halogenated amino acid salt for a time sufficient to disinfect and/or clean the lens. | 03-24-2011 |
| 20110060044 | ALIPHATIC ACID-CONTAINING N-HALOGENATED AMINO ACID FORMULATIONS - The present invention relates to methods for treating an infected tissue comprising treating the infected tissue with a formulation comprising a N-halogenated amino acid and an aliphatic acid. This specification also discloses methods for improving the antimicrobial activity of a formulation comprising a N-halogenated amino acid, the method comprising adding an aliphatic acid to said formulation. | 03-10-2011 |
| 20110059039 | USE OF PEO-PBO BLOCK COPOLYMERS IN OPHTHALMIC COMPOSITIONS - The use of poly(oxyethylene)-poly(oxybutylene) block copolymers in pharmaceutical compositions useful for modifying the surfaces of contact lenses and other medical devices is disclosed. The present invention is based in-part on a discovery that this class of compounds is particularly efficient in wetting hydrophobic surfaces, such as the surfaces of silicone hydrogel contact lenses and other types of ophthalmic lenses. Such compounds are also useful for cleaning purposes. The use of the compounds as surfactants in various types of compositions for treating contact lenses therefore represents a preferred embodiment of the present invention. | 03-10-2011 |
| 20110009322 | USE OF BRADYKININ AND RELATED B2R AGONISTS TO TREAT OCULAR HYPERTENSION AND GLAUCOMA - The invention provides methods for treating and/or preventing ocular disorders associated with increased intraocular pressure comprising administering a bradykinin B | 01-13-2011 |
| 20110008276 | ETHYLENEOXIDE BUTYLENEOXIDE BLOCK COPOLYMER COMPOSITIONS - The present invention relates to compositions comprising ethyleneoxide butyleneoxide and a galactomannan such as guar. The compositions are particularly well suited for ophthalmic applications such as contact lens disinfection and rewetting. Methods for the treatment of dry eye using the compositions of the present invention are also contemplated. | 01-13-2011 |
| 20110003803 | COMPOSITIONS AND METHODS FOR TREATING OPHTHALMIC, OTIC, OR NASAL INFECTIONS - The present invention relates to methods for treating an ophthalmic, otic, or nasal infection comprising treating the infected tissue with a composition comprising finafloxacin or a finafloxacin derivative. The present invention also relates to antimicrobial compositions comprising finafloxacin or a finafloxacin derivative. The compositions are suitable for the treatment of ophthalmic, otic, or nasal infections. | 01-06-2011 |
| 20100305193 | RNAI-MEDIATED INHIBITION OF GREMLIN FOR TREATMENT OF IOP-RELATED CONDITIONS - RNA interference is provided for inhibition of gremlin in intraocular pressure-related conditions, including ocular hypertension and glaucoma such as normal tension glaucoma and open angle glaucoma. | 12-02-2010 |
| 20100303930 | N-HALAMINE FORMULATIONS WITH ENHANCED ANTIMICROBIAL ACTIVITY - The present invention relates to antimicrobial formulations comprising an N-halamine and a quantity of sodium chlorite sufficient to enhance the antimicrobial efficacy of the N-halamine. The present invention is further directed to formulations for disinfecting a contact lens comprising an N-halamine and a quantity of sodium chlorite sufficient to enhance the antimicrobial efficacy of the N-halamine. | 12-02-2010 |
| 20100267811 | RNAi-RELATED INHIBITION OF TNFa SIGNALING PATHWAY FOR TREATMENT OF OCULAR ANGIOGENESIS - RNA interference is provided for inhibition of tumor necrosis factor α (TNFα) by silencing TNFα cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNFα converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNFα targets, in particular, is useful for treating patients having a TNFα-related condition or at risk of developing a TNFα-related condition, such as ocular angiogenesis, retinal ischemia, and diabetic retinopathy. | 10-21-2010 |
| 20100266664 | Devices And Methods For Ophthalmic Drug Delivery - Disclosed are ophthalmic drug-delivery devices, comprising a body having a proximal end and a distal end, wherein the body includes a styrene elastomer matrix and a drug in contact with the matrix. Also disclosed are methods of treating or preventing an eye disease in a subject, that involve contacting an eye of the subject with an ophthalmic drug delivery device comprising a body having a proximal end and a distal end, wherein the body comprises a styrene elastomer matrix and a drug in contact with the matrix, wherein release of the drug from the device occurs over time following contacting of the device with the eye of the subject. | 10-21-2010 |
| 20100260784 | PAI-1 BINDING MODULATORS FOR THE TREATMENT OF OCULAR DISORDERS - The invention concerns in one embodiment a method for treating glaucoma or elevated IOP in a patient comprising administering to the patient an effective amount of a composition comprising an agent that modulates PAI-1 binding to vitronectin. In another embodiment, the invention concerns a method of manufacturing a compound to be used as a treatment for glaucoma or elevated IOP comprising providing a candidate substance suspected of modulating PAI-1 binding, selecting the compound by assessing the ability of the candidate substance to decrease the amount of active PAI-1 in the trabecular meshwork of a subject suffering from glaucoma or elevated PAI-1, and manufacturing the selected compound. | 10-14-2010 |
| 20100247548 | ANTAGONISTS OF CI-M6P/IGF2R FOR PREVENTION AND TREATMENT OF CTGF-MEDIATED OCULAR DISORDERS - Antagonists of cation-independent mannose 6-phosphate/insulin-like growth factor-II receptor are provided for attenuation of CTGF signaling in a method of down-regulation of receptor signaling and downstream decreased signaling of connective tissue growth factor in ocular disorders involving inappropriate CTGF signaling. Ocular disorders involving inappropriate CTGF signaling include ocular hypertension, glaucoma, glaucomatous retinopathy, optic neuropathy, macular degeneration, diabetic retinopathy, choroidal neovascularization, and proliferative vitreoretinopathy, for example. Such disorders are treated by administering antagonists of the present invention. | 09-30-2010 |
| 20100227905 | Pharmaceutical Composition for Delivery of Receptor Tyrosine Kinase Inhibiting (RTKi) Compounds to the Eye - The present invention relates to development of efficacious pharmaceutical compositions in the form of aqueous solutions comprising an active agent in a therapeutically effective amount and a polyethylene glycol having a molecular weight of at least 2000. | 09-09-2010 |
| 20100227904 | Pharmaceutical Composition for Delivery of Receptor Tyrosine Kinase Inhibiting (RTKi) Compounds to the Eye - The present invention relates to development of efficacious pharmaceutical implant compositions comprising an active agent in a therapeutically effective amount and a polyethylene glycol having a molecular weight of at least 2000. | 09-09-2010 |
| 20100226992 | Pharmaceutical Composition for Delivery of Receptor Tyrosine Kinase Inhibiting (RTKi) Compounds to the Eye - The present invention relates to development of efficacious pharmaceutical compositions in the form of intraocular suspensions comprising an anti-angiogenic compound in a therapeutically effective amount and a polyethylene glycol having a molecular weight of at least 2000, preferably at least 3000. | 09-09-2010 |
| 20100210730 | N-HALOGENATED AMINO ACID FORMULATIONS WITH ANTI-INFLAMMATORY COMPOUNDS - The present invention relates to a formulation having antimicrobial activity comprising a N-halogenated amino acid and a anti-inflammatory compound. This specification also describes methods for treating a tissue infection comprising contacting the infected tissue with a pharmaceutically effective amount of a formulation comprising a N-halogenated amino acid and a anti-inflammatory compound. This specification further describes a method for treating respiratory infections comprising contacting the site of the respiratory infection with a pharmaceutically effective amount of a formulation comprising a N-halogenated amino acid and a anti-inflammatory compound. | 08-19-2010 |
| 20100204584 | METHOD AND APPARATUS FOR OCULAR SURFACE IMAGING - The invention provides apparatuses and methods for detecting corneal surface defects. The methods and/or an apparatus of the invention can be used to detect corneal surface diseases, such as dry eye. | 08-12-2010 |
| 20100204181 | N-HALOGENATED AMINO ACID FORMULATIONS COMPRISING PHOSPHINE OR AMINE OXIDES - The present invention relates to methods for treating an infected tissue comprising treating the infected tissue with a formulation comprising a N-halogenated amino acid and a phosphine oxide or amine oxide. This specification also discloses methods for improving the antimicrobial activity of a formulation comprising a N-halogenated amino acid, the method comprising adding a phosphine oxide or amine oxide to said formulation. | 08-12-2010 |
| 20100196415 | PROCESS FOR PURIFYING GUAR - The present invention relates to processes for purifying guar comprising combining borate and guar in an aqueous solution and treating the aqueous solution with an organic solvent to induce precipitation of purified guar. Another embodiment of the present invention is directed to ophthalmic formulations comprising purified guar produced by the processes described. | 08-05-2010 |
| 20100183629 | ANTAGONISTS OF ENDOTHELIAL DIFFERENTIATION GENE SUBFAMILY 3 (EDG-3, S1P3) RECEPTORS FOR PREVENTION AND TREATMENT OF OCULAR DISORDERS - Antagonists of S1P3 (Edg-3) receptors are provided for attenuation of Smad signaling in a method of down-regulation of receptor signaling and downstream decreased production of connective tissue growth factor in ocular disorders involving CTGF accumulation. Ocular disorders involving inappropriate CTGF accumulation include ocular hypertension, glaucoma, glaucomatous retinopathy, optic neuropathy, macular degeneration, diabetic retinopathy, choroidal neovascularization, proliferative vitreoretinopathy and ocular wound healing, for example. Such disorders are treated by administering antagonists of the present invention. | 07-22-2010 |
| 20100166676 | RNAi-MEDIATED INHIBITION OF TUMOR NECROSIS FACTOR ALPHA-RELATED CONDITIONS - RNA interference is provided for inhibition of tumor necrosis factor α (TNFα) by silencing TNFα cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNFα converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNFα targets, in particular, is useful for treating patients having a TNFα-related condition or at risk of developing a TNFα-related condition such as the ocular conditions dry eye, allergic conjunctivitis, or ocular inflammation, or such as dermatitis, rhinitis, or asthma, for example. | 07-01-2010 |
| 20100160870 | Two Piece Housing For Drug Loading - A drug loading apparatus has a dispensing chamber housing formed by a top housing part and a bottom housing part. The top housing part is separable from the bottom housing part. A plunger is located in the bottom housing part such that the plunger forms a first fluid seal with an inner wall of the bottom housing part. When the top housing part is coupled to the bottom housing part, a second fluid seal is formed. | 06-24-2010 |
| 20100160342 | Compositions of Topical Ocular Solutions to Deliver Effective Concentrations of Active Agent to the Posterior Segment of the Eye - The present invention relates to development of efficacious pharmaceutical compositions comprising an active agent, such as the free base or hydrochloride salt of tandospirone, for topical delivery to the eye for the treatment of retinal disorders. | 06-24-2010 |
| 20100160298 | METHOD OF TREATING OCULAR ALLERGY - The topical use of 5,6,7-trihydroxyheptanoic acid and analogs alone or in combination with histamine antagonists and/or mast cell stabilizers is disclosed for the treatment of ocular allergy. | 06-24-2010 |
| 20100159029 | COMPOSITION AND NUTRITIONAL SUPPLEMENTS FOR IMPROVING OCULAR HEALTH AND REDUCING OCULAR INFLAMMATORY RESPONSE - The present invention provides improved dietary supplements and methods for inhibiting the progression of macular degeneration and promoting healthy vision, while at the same time maintaining general health. The dietary supplements of the invention contain vitamin E and carotenoids in the form of lutein and/or zeaxanthine. The dietary supplements of the invention further contain Vitamin D, Vitamin C, copper and zinc and may also contain such ingredients as rosemary, DHA, and other vitamins and minerals. | 06-24-2010 |
| 20100158897 | PAI-1 MODULATORS FOR THE TREATMENT OF OCULAR DISORDERS - The invention concerns in one embodiment a method for treating glaucoma or elevated IOP in a patient comprising administering to the patient an effective amount of a composition comprising an agent that modulates PAI-1 activity. In a preferred embodiment, the agent that modulates PAI-1 expression and/or activity is cilostazol or an analog or metabolite of cilostazol. | 06-24-2010 |
| 20100152676 | Drug Loading Through Plunger - A drug loading apparatus includes a plunger with a through hole or slit valve located in the top face of the plunger. A dispensing chamber housing located in a drug delivery device is configured to receive the plunger so that a dispensing chamber is formed when the plunger is located in the dispensing chamber housing. The drug can then be loaded into the dispensing chamber through the plunger, and a piston with an end configured to seal the through hole or engage the plunger with the slit valve can then be inserted. | 06-17-2010 |
| 20100144844 | RNAi-MEDIATED INHIBITION OF H1F1A FOR TREATMENT OF OCULAR ANGIOGENESIS - RNA interference is provided for inhibition of HIF1A mRNA expression for treating patients with ocular angiogenesis, particularly for treating retinal edema, diabetic retinopathy, sequela associated with retinal ischemia, posterior segment neovascularization (PSNV), and neovascular glaucoma, and for treating patients at risk of developing such conditions. | 06-10-2010 |
| 20100120851 | PRENYLTRANSFERASE INHIBITORS FOR OCULAR HYPERTENSION CONTROL AND THE TREATMENT OF GLAUCOMA - The invention concerns in one embodiment a method of treating glaucoma or elevated intraocular pressure comprising administering a pharmaceutically effective amount of a composition comprising at least one prenyltransferase inhibitor. In another embodiment, the invention concerns a composition for the treatment of elevated intraocular pressure and glaucoma comprising a pharmaceutically effective amount of a prenyltransferase inhibitor. | 05-13-2010 |
| 20100120741 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE - The present invention relates to compounds and methods which may be useful as inhibitors of H | 05-13-2010 |
| 20100113481 | USE OF SERUM AMYLOID A GENE IN DIAGNOSIS AND TREATMENT OF GLAUCOMA AND IDENTIFICATION OF ANTI-GLAUCOMA AGENTS - The present invention provides compositions and methods for treating glaucoma, methods for diagnosing glaucoma, and methods for identifying agents which may be useful in the treatment of glaucoma. More specifically, the present invention describes the use of agents that modulate the expression of serum amyloid A, wherein such agents are inhibitors of p38 MAPkinase. | 05-06-2010 |
| 20100106083 | Method of Operating Ophthalmic Hand Piece with Disposable End - The present invention is a method of operating an ophthalmic hand piece. A connection between a tip segment and a limited reuse assembly is recognized. A type of tip segment connected to the limited reuse assembly is determined. Dosage information is received. A first input is received. In response to the first input, a heater is activated to heat a substance contained in a dispensing chamber. After the substance has reached a desired temperature range, the dosage information is used to control a distance a plunger travels. A second input is received. In response to the second input a motor is activated, and the drug is delivered into the eye. | 04-29-2010 |
| 20100069842 | Ceramic Chamber With Integrated Temperature Control Device For Ophthalmic Medical Device - A dispensing assembly includes a dispensing chamber housing, a needle with a needle hub, and a temperature control device. The dispensing chamber housing has an inner surface and an outer surface. The inner surface partially defines a dispensing chamber for receiving a quantity of a substance. The dispensing chamber housing is made of a sintered ceramic. The needle is fluidly coupled to the dispensing chamber. The temperature control device is encapsulated in the dispensing chamber housing during a sintering process. The temperature control device is configured to alter a temperature of a substance in the dispensing chamber. | 03-18-2010 |
| 20100063047 | AMINOPYRIMIDINE INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE - The present invention relates to compounds and methods which may be useful as inhibitors of H | 03-11-2010 |
| 20090326044 | RNAi-Mediated Inhibition of Ocular Targets - RNA interference is provided for inhibition of ocular hypertension target mRNA expression for lowering elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Ocular hypertension targets include carbonic anhydrase II, IV, and XII; β1- and β2 adrenergic receptors; acetylcholinesterase; Na | 12-31-2009 |
| 20090324507 | RNAi-Mediated Inhibition of Spleen Tyrosine Kinase-Related Inflammatory Conditions - RNA interference is provided for inhibition of spleen tyrosine kinase (Syk) mRNA expression, in particular, for treating patients having a Syk-related inflammatory condition or at risk of developing a Syk-related inflammatory condition such as allergic conjunctivitis, ocular inflammation, dermatitis, rhinitis, asthma, allergy, or mast-cell disease. | 12-31-2009 |
| 20090275641 | RNAi-Mediated Inhibition of RHO Kinase for Treatment of Ocular Disorders - RNA interference is provided for inhibition of Rho kinase mRNA expression for treating patients with ocular disorders, particularly for treating intraocular pressure, ocular hypertension and glaucoma. Rho kinase mRNA targets include mRNA for ROCK1 and ROCK2. | 11-05-2009 |
| 20090274631 | RNAi-Mediated Inhibition of Histamine Receptor H1-Related Conditions - RNA interference is provided for inhibition of histamine receptor H1 mRNA expression, in particular, for treating patients having an HRH1-related condition or at risk of developing an HRH1-related condition such as allergic conjunctivitis, ocular inflammation, dermatitis, rhinitis, asthma, or allergy. | 11-05-2009 |
| 20090270345 | POLYMERIC ARTIFICIAL TEAR SYSTEM - The present invention relates to artificial tear formulations and ophthalmic formulations suitable for drug delivery. The formulations comprise galactomannans such as guar or hydroxypropyl guar and a borate source such as boric acid. The formulations further comprise a cis-diol such as sorbitol that interferes with the cross-linking of galactomannan and borate. Optionally, the formulations are substantially free of divalent cations. | 10-29-2009 |
| 20090264375 | INTRAOCULAR IRRIGATING SOLUTIONS AND METHODS FOR TREATING CORNEAL EDEMA - One aspect of the present invention relates to methods of treating corneal edema comprising contacting a cornea with an ophthalmic irrigating composition comprising histidine. In certain embodiments, the ophthalmic irrigating compositions contact the corneal endothelium. Another aspect of the present invention relates to ophthalmic irrigating compositions for treating corneal edema comprising histidine and optionally, calcium glycerophosphate and/or glutathione disulfide. | 10-22-2009 |
| 20090247936 | STREAMLINED ULTRASONIC DEVICE AND METHOD OF USE - A phacoemulsification device that features an applicator tip as in a cutting tip for insertion into an eye and into contact with a cataract. The device includes a shaft having a phacoemulsification movement generator connector end at a proximal location and an applicator tip supporting end at a distal end, and the shaft further includes a shaft section that extends in a region positioned between the proximal and distal ends of the shaft, and the shaft section having a convoluted exposed surface which includes longitudinally extending projections and longitudinally extending valleys arranged in sequence about the circumference of the shaft section. The projections are formed in an exemplary embodiment as to be free of any edges as in, for example, an embodiment that includes projections and valleys that have smooth sloped curving walls in cross section and which smooth sloped curving walls include a plurality of mirror image S-shaped regions extending from a maximum radial extension region of a first projection, down to a maximum depth valley region of a first valley and up to a maximum radial projection of a second projection, with the valley region being positioned between respective first and second projections. | 10-01-2009 |
| 20090239957 | STABILIZED GLYCEROPHOSPHATE-CONTAINING SURGICAL IRRIGATING SOLUTION - One aspect of the present invention relates to stabilized irrigating compositions comprising sodium glycerophosphate and/or calcium glycerophosphate, and a bicarbonate salt. Another aspect of the present invention relates to methods of irrigating ocular tissues during a surgical procedure comprising bathing the intraocular tissues with an irrigating composition comprising sodium glycerophosphate and/or calcium glycerophosphate, and a bicarbonate salt. | 09-24-2009 |
| 20090209627 | RNAi-MEDIATED INHIBITION OF CONNEXIN 43 FOR TREATMENT OF IOP-RELATED CONDITIONS - RNA interference is provided for inhibition of connexin 43 (Cx43) in intraocular pressure-related conditions, including ocular hypertension and glaucoma such as normal tension glaucoma and open angle glaucoma. | 08-20-2009 |
| 20090209574 | FLUOROQUINOLONE DERIVATIVES FOR OPHTHALMIC APPLICATIONS - The present invention relates to fluoroquinolone derivatives having enhanced ocular penetration characteristics and/or antimicrobial activity, and to compositions comprising such derivatives. The derivatives and compositions are particularly well suited for treating ophthalmic bacterial infections. The present invention more particularly relates to the discovery that a 2-methyl substitution on a diazabicyclo group attached to a fluoroquinolone ring system produces improved permeability characteristics, and that a 5-amino substitution on a fluoroquinolone ring system results in improved anti-microbial activity. | 08-20-2009 |
| 20090202524 | PAI-1 EXPRESSION AND ACTIVITY INHIBITORS FOR THE TREATMENT OF OCULAR DISORDERS - The invention concerns in one embodiment a method for treating glaucoma or elevated IOP in a patient comprising administering to the patient an effective amount of a composition comprising an agent that inhibits PAI-1 expression or PAI-1 activity. Another embodiment of the present invention is a method of treating a PAI-1-associated ocular disorder in a subject in need, comprising administering to the patient an effective amount of a composition comprising an agent that inhibits PAI-1 activity or expression. | 08-13-2009 |
| 20090197838 | ANTIMICROBIAL N-HALOGENATED AMINO ACID SALTS - The present invention relates to a formulation comprising a N-halogenated amino acid and a phase transfer agent. The present invention also describes a method for disinfecting and/or cleaning a contact lens comprising contacting a contact lens with a formulation comprising a N-halogenated amino acid salt for a time sufficient to disinfect and/or clean the lens. | 08-06-2009 |
| 20090156667 | METHOD OF TREATING ASTHMA, ALLERGIC RHINITIS, AND SKIN DISORDERS - The use of 5,6,7-trihydroxyheptanoic acid and analogs is disclosed for the treatment of asthma, allergic rhinitis, and skin disorders such as allergic dermatitis, contact hypersensitivity, urticaria (hives), rosacea, or psoriasis. | 06-18-2009 |
| 20090137539 | TOPICAL OPHTHALMIC OR OTIC SOLUTION FORMULATIONS CONTAINING MOXIFLOXACIN HYDROCHLORIDE AND DEXAMETHASONE PHOSPHATE - Topical ophthalmic and otic solution compositions of moxifloxacin and dexamethasone phosphate are disclosed. | 05-28-2009 |
| 20090131449 | USE OF TRPV1 RECEPTOR ANTAGONISTS FOR TREATING DRY EYE AND OCULAR PAIN - Methods of treating symptoms of dry eye by administering inhibitors of transient receptor potential cation channel, subfamily V, member 1 (TRPV1) are disclosed. Methods of preventing or alleviating ocular pain by administering TRPV1 inhibitors are also disclosed. | 05-21-2009 |
| 20090131358 | LOW DENSITY LIPOPROTEIN RECEPTOR-MEDIATED siRNA DELIVERY - The invention provides interfering RNA molecule-ligand conjugates useful as a delivery system for delivering interfering RNA molecules to a cell in vitro or in vivo. The conjugates comprise a ligand that can bind to a low density lipoprotein receptor (LDLR) or LDLR family member. Therapeutic uses for the conjugates are also provided. | 05-21-2009 |
| 20090118456 | CHELATING SILICON-BASED POLYMERS - The present invention relates to novel silicon-based polymers, particularly silicon-based polymers having citrate groups, and their use as chelating agents, for forming and as stabilizers. | 05-07-2009 |
| 20090117098 | Complement C1Q Inhibitors For The Prevention And Treatment Of Glaucoma - The invention concerns in one embodiment a method of treating glaucoma or elevated intraocular pressure comprising administering a pharmaceutically effective amount of a composition comprising a Complement C1q inhibitor. In another embodiment, the invention concerns a composition for the treatment of elevated intraocular pressure and glaucoma, the composition comprising a pharmaceutically effective amount of a Complement C1q inhibitor. | 05-07-2009 |
| 20090105182 | RNAi-MEDIATED INHIBITION OF STROMAL CELL-DERIVED FACTOR 1-RELATED TARGETS FOR TREATMENT OF NEOVASCULARIZATION-RELATED CONDITIONS - RNA interference is provided for inhibition of stromal cell-derived factor 1 (SDF1)-related targets in pathologic neovascularization-related conditions, including those cellular changes resulting from the signal transduction activity of the SDF1 targets that lead directly or indirectly to ocular neovascularization, abnormal angiogenesis, retinal vascular permeability, retinal edema, diabetic retinopathy particularly proliferative diabetic retinopathy, diabetic macular edema, exudative age-related macular degeneration, sequela associated with retinal ischemia, and posterior segment neovascularization, for example. | 04-23-2009 |
| 20090098136 | USE OF TNF RECEPTOR ANTAGONISTS FOR TREATING DRY EYE - Methods of treating dry eye by administering inhibitors of tumor necrosis factor α (TNFα) are disclosed. | 04-16-2009 |
| 20090093789 | Method of Delivering A Rate And Temperature - Dependent Substance Into The Eye - A method of injecting a mixture into an eye includes: providing the mixture in a dispensing chamber with an air gap located between the mixture and an interior surface of a dispensing chamber housing, when the mixture and dispensing chamber housing are near room temperature; bringing the dispensing chamber housing and mixture to a temperature range, other than near room temperature, at which the mixture expands and is in a more liquid state; maintaining air in a needle after the mixture expands and prior to an injection; selecting a drug release rate; and injecting the mixture so as to form a shape with a surface area that results in the selected drug release rate. | 04-09-2009 |
| 20090093788 | Thermal Coefficient Driven Drug Pellet Size For Ophthalmic Injection - A method of injecting a mixture into an eye includes: providing the mixture in a dispensing chamber with an air gap located between the mixture and an interior surface of a dispensing chamber housing, when the mixture and dispensing chamber housing are near room temperature; bringing the dispensing chamber housing and mixture to a temperature range at which the mixture expands and is in a more liquid state; maintaining air in a needle after the mixture expands and prior to an injection; and injecting the air in the needle and the mixture into the eye. | 04-09-2009 |
| 20090087413 | SELF-COMPLEMENTARY AAV-MEDIATED DELIVERY OF INTERFERING RNA MOLECULES TO TREAT OR PREVENT OCULAR DISORDERS - The invention provides methods for delivering interfering RNA molecules to an eye of a patient to treat ocular disorders. In particular, the methods of the invention comprise the use of a self-complementary adeno-associated (scAAV) viral vector that can deliver an interfering RNA molecule to an eye of a patient to inhibit expression of a gene that is associated with an ocular disorder. | 04-02-2009 |
| 20090054365 | RNAi-MEDIATED INHIBITION OF AQUAPORIN 1 FOR TREATMENT OF OCULAR NEOVASCULARIZATION - RNA interference is provided for inhibition of aquaporin 1 (AQP1) to treat conditions associated with neovascularization. | 02-26-2009 |
| 20090036397 | RNAi-RELATED INHIBITION OF TNFa SIGNALING PATHWAY FOR TREATMENT OF MACULAR EDEMA - RNA interference is provided for inhibition of tumor necrosis factor α (TNFα) by silencing TNFα cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNFα converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNFα targets, in particular, is useful for treating patients having or at risk of developing macular edema. | 02-05-2009 |
| 20090036396 | RNAi-RELATED INHIBITION OF TNFalpha SIGNALING PATHWAY FOR TREATMENT OF OCULAR ANGIOGENESIS - RNA interference is provided for inhibition of tumor necrosis factor α (TNFα) by silencing TNFα cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNFα converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNFα targets, in particular, is useful for treating patients having a TNFα-related condition or at risk of developing a TNFα-related condition, such as ocular angiogenesis, retinal ischemia, and diabetic retinopathy. | 02-05-2009 |
| 20090035225 | RNAi-RELATED INHIBITION OF TNFa SIGNALING PATHWAY FOR TREATMENT OF GLAUCOMA - RNA interference is provided for inhibition of tumor necrosis factor α (TNFα) by silencing TNFα cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNFα converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNFα targets, in particular, is useful for treating patients having a TNFα-related condition or at risk of developing a TNFα-related condition such as the ocular conditions associated with elevated intraocular pressure (IOP), including glaucoma and ocular hypertension. | 02-05-2009 |
| 20090012030 | RNAi-MEDIATED INHIBITIN OF HTRA1 FOR TREATMENT OF MACULAR DEGENERATION - RNA interference is provided for inhibition of HTRA1 mRNA expression for treating patients with an HTRA1-mediated ocular disorder. In particular, methods are provided for treating age-related macular degeneration (AMD) and using interfering RNA molecules that attenuate expression of HTRA1 in patients having AMD or at risk of developing AMD. | 01-08-2009 |
| 20080305514 | METHOD FOR DETECTING MICROBES - The present invention relates to methods for detecting microbes in a sample comprising filtering the sample through a fluid-permeable surface, contacting the surface with a viability stain, scanning the surface for viability stain to form a first scan, contacting the surface with a nucleic acid stain, scanning the surface for nucleic acid stain to form a second scan, and comparing said first scan and said second scan. | 12-11-2008 |
| 20080287395 | Phospholipid Compositions for Contact Lens Care and Preservation of Pharmaceutical Compositions - The use of certain synthetic phospholipids to preserve pharmaceutical compositions from microbial contamination is described. The synthetic phospholipids have unique molecular arrangements wherein a phosphate group is linked to a quaternary ammonium functionality via a substituted-propenyl group, and the quaternary ammonium functionality is further linked to at least one long hydrocarbon chain. Such molecular arrangements are what make the phospholipids of formula (I) highly water soluble, e.g., the length of the hydrocarbon chain assists to maintain solubility and efficacy of the molecules for the uses described herein. The synthetic phospholipids described herein have been found to be particularly useful as antimicrobial preservatives for ophthalmic, otic and nasal pharmaceutical compositions, especially ophthalmic compositions. These compounds may also be utilized to disinfect contact lenses. The invention is based in-part upon a finding that the antimicrobial activity of the synthetic phospholipids is affected by the ionic strength of the compositions in which the compounds are contained. The provision of compounds having limited ionic strengths is therefore preferred. | 11-20-2008 |
| 20080275126 | ALIPHATIC ACID-CONTAINING N-HALOGENATED AMINO ACID FORMULATIONS - The present invention relates to methods for treating an infected tissue comprising treating the infected tissue with a formulation comprising a N-halogenated amino acid and an aliphatic acid. This specification also discloses methods for improving the antimicrobial activity of a formulation comprising a N-halogenated amino acid, the method comprising adding an aliphatic acid to said formulation. | 11-06-2008 |
| 20080275123 | N-HALOGENATED AMINO ACID FORMULATIONS - The present invention relates to a method for treating a tissue infection comprising contacting the infected tissue with a pharmaceutically effective amount of a formulation comprising a N-halogenated amino acid and a phase transfer agent. This specification also describes a formulation having antimicrobial activity comprising a N-halogenated amino acid and a phase transfer agent. | 11-06-2008 |
| 20080275122 | N-HALOGENATED AMINO ACID FORMULATIONS WITH ANTI-INFLAMMATORY COMPOUNDS - The present invention relates to a formulation having antimicrobial activity comprising a N-halogenated amino acid and a anti-inflammatory compound. This specification also describes methods for treating a tissue infection comprising contacting the infected tissue with a pharmaceutically effective amount of a formulation comprising a N-halogenated amino acid and a anti-inflammatory compound. This specification further describes a method for treating respiratory infections comprising contacting the site of the respiratory infection with a pharmaceutically effective amount of a formulation comprising a N-halogenated amino acid and a anti-inflammatory compound. | 11-06-2008 |
| 20080275121 | N-HALOGENATED AMINO ACID FORMULATIONS AND METHODS FOR CLEANING AND DISINFECTION - The present invention relates to methods for disinfecting or cleaning a contact lens comprising contacting a contact lens with a formulation comprising a N-halogenated amino acid and a phase transfer agent for a time sufficient to disinfect or clean the lens. This specification further discloses a formulation for disinfecting a contact lens comprising an N-halogenated amino acid and a phase transfer agent. | 11-06-2008 |
| 20080269418 | OPHTHALMIC AND OTORHINOLARYNGOLOGICAL DEVICE MATERIALS CONTAINING PHENYLENE-SILOXANE MACROMERS - Disclosed are soft, high refractive index, acrylic device materials having improved strength. The materials contain a phenylene-siloxane macromer. | 10-30-2008 |
| 20080266519 | UV-ABSORBERS FOR OPHTHALMIC LENS MATERIALS - 1,4-disubstituted-1,2,3-triazole UV absorbing monomers are disclosed. The UV absorbers are particularly suitable for use in intraocular lens materials. | 10-30-2008 |
| 20080254029 | Use of an Inhibitor of TNFa Plus an Antihistamine to Treat Allergic Rhinitis and Allergic Conjunctivitis - Disclosed are methods of treating allergic conjunctivitis and allergic rhinitis in a subject that involve topically administering to the subject a composition comprising a pharmaceutically effective amount of an H | 10-16-2008 |
| 20080199537 | TOPICAL GATIFLOXACIN FORMULATIONS - Topical ophthalmic solution compositions of gatifloxacin are disclosed. The compositions do not contain disodium edetate or any other metal chelating agent. | 08-21-2008 |
